Objective: To investigate A-delta fiber pathways in patients with large, mixed, and small fiber neuropathies using pain-related evoked potentials (PREP).
Introduction
Symptoms of small nerve fiber damage are common in patients with polyneuropathies which are then termed mixed fiber neuropathies (MFN) to discriminate from patients with pure large fiber neuropathy (LFN) or small fiber neuropathy (SFN) (Abbott et al., 2011; Hansen et al., 2015; Colloca et al., 2017) . While LFN is diagnosed based on clinical examination and nerve conduction studies, SFN is defined by clinical, histopathological, and/or functional criteria, excluding patients with signs of large fiber involvement (Devigili et al., 2008) . The mechanisms leading to damage of different nerve fiber types are incompletely understood and evolution of SFN to MFN and LFN to MFN is possible (Spallone et al., 2013; Abraham et al., 2016) . Characterization of small fiber pathology and its clinical impact in patients with MFN remains challenging (Schaefer et al., 2014; de Greef et al., 2018) .
Diverse techniques have been developed for small nerve fiber assessment addressing histology (e.g. intraepidermal nerve fiber density, IENFD), morphology (e.g. corneal confocal microscopy), and function (e.g. quantitative sensory testing, QST) (Rolke et al., 2006; Lauria et al., 2010; Papanas et al., 2013) . To investigate A-delta nerve fiber conduction, pain-related evoked potentials (PREP) are a suitable method (Katsarava et al., 2006a) . PREP are a valuable tool for the non-invasive diagnostic workup and screening of small fiber pathology (Obermann et al., 2008; Yoon et al., 2011; Papagianni et al., 2018) . While most studies using PREP focused on SFN (Katsarava et al., 2006b; Müller et al., 2010; Üçeyler et al., 2013; Siedler et al., 2019) , diagnostic implications of PREP in patients with MFN have so far been mostly assessed in small patient cohorts (Hansen et al., 2015) .
The aim of this study was to characterize small fiber impairment in a large cohort of patients with neuropathies of different origin and to investigate the diagnostic value of PREP in these patients.
Subjects and Methods

Patients and healthy controls
Our study was approved by the Würzburg Medical Faculty Ethics Committee (#37/09) and written informed consent was obtained from all study participants before inclusion. We prospectively enrolled consecutive and unselected 108 adult patients ≥18 years (74 men, 34 women) with confirmed polyneuropathy (PNP) who were seen as in-and out-patients using clinical, electrophysiological, and/or histological criteria at the Department of Neurology, University of Würzburg, Germany. Patients diagnosed with epilepsy and those carrying pacemakers, implantable cardioverter defibrillators, or brain stimulators were excluded.
Additionally, we enrolled 49 age-and gender-matched adult healthy controls ≥18 years (25 men, 24 women) from among patients` relatives and friends, applying the same exclusion criteria in addition to the presence of neuropathic pain or other sources of pain. All healthy controls underwent clinical assessment including a medical interview and pain questionnaires, sural nerve conduction studies, and QST to exclude neuropathy (for details see below).
Clinical examination, questionnaires, and laboratory assessment
All patients were examined neurologically, and detailed medical history was recorded.
Large fiber neuropathy (LFN) was diagnosed, if typical clinical signs and symptoms were present (e.g. paresis, hypoesthesia, loss of proprioception and/or impaired vibration sense, areflexia) and nerve conduction studies revealed damage of large motor and/or sensory nerves, and if neuropathic pain was missing. Mixed fiber neuropathy (MFN) was assumed, if patients additionally reported neuropathic pain as a symptom of small nerve fibers (Hansen et al., 2015) . Small fiber neuropathy (SFN) was diagnosed, if patients had pathological findings in at least two of the following three tests (Devigili et al., 2008) : neurological examination, quantitative sensory testing (QST), and distal skin punch biopsy, but no clinical or electrophysiological signs of large fiber neuropathy.
Stratification for axonal or demyelinating pathology was based on both histopathological criteria (in case a nerve biopsy was performed) and electrophysiological criteria, each case was evaluated independently by two experts in the field (N.Ü., C.S.).
The Neuropathic Pain Symptom Inventory (NPSI) (Bouhassira et al., 2004; Sommer et al., 2011) and the Graded Chronic Pain Scale (GCPS) (Von Korff et al., 1992) were used for standardized pain characterization. For depressive symptoms, the "Allgemeine Depressionsskala" (ADS) (Radloff, 1977; Hautzinger 1993 ) was applied. Questionnaires were filled in by patients and healthy controls. Patients additionally underwent laboratory analysis as individually needed including blood count, C reactive protein, blood sedimentation rate, parameters of liver and kidney function, immunoglobulins, vitamin B12, thyroidea-stimulating hormone, and screening for autoimmune diseases, including rheumatoid factor, and anti-nucleotid antibodies. If indicated, a lumbar puncture was performed for analysis of leucocyte count, protein, and glucose levels.
Nerve conduction studies
Nerve conduction studies were performed following established protocols (Kimura, 2001) . In all patients, the sural and tibial nerve was assessed as baseline investigation; in 103/108 patients (95%) of patients a second, and in 73/108 (68%) of patients a third motor nerve were studied. Additional nerve conduction studies were performed as initiated by the treating physician in routine. Demyelinating LFN was diagnosed by predominant prolonged distal motor latency (dml) and reduced nerve conduction velocity (NCV), axonal LFN was diagnosed in case of predominant reduction of amplitudes (regardless of etiology). If a sural nerve biopsy was performed, histopathological changes were also taken into account.
QST
QST was performed as described previously (Üçeyler et al., 2010) using a calibrated thermode (Somedic, Hörby, Sweden) and following a standardized procedure as previously described (Rolke et al., 2006) . In patients, tests were done at the dorsum of one foot (test area) and at the cheek (control area). In healthy controls, QST was performed at the left foot and the cheek. Based on the log transformed raw values for each QST item, a z-score sensory profile was calculated as follows: z-score = (value of the subject -mean value of controls)/standard deviation of controls. Negative z-scores indicate loss of sensation, positive z-scores indicate gain of sensation. The following parameters were assessed: cold and heat detection thresholds (CDT, HDT), detection of temperature changes (thermal sensory limen, TSL), paradoxical heat sensation (PHS, i.e. reporting heat after a cold stimulus), heat and cold pain thresholds (HPT, CPT), pressure pain threshold (PPT), and mechanical pain sensitivity (MPS) and mechanical detection threshold (MDT), mechanical pain threshold (MPT), vibration detection threshold (VDT), and wind-up-ratio for muscular pressure pain (WUR). QST was evaluated separately for male and female patients due to different normative values.
Pain-related evoked potentials (PREP)
PREP were performed as previously described (Üçeyler et al., 2013) . Potentials were generated using superficial planar concentric electrodes (Inomed Medizintechnik GmbH, Lübeck, Germany) and a stimulator (Digitimer DS7A, Welwyn Garden City, UK). Defined body sites were stimulated bilaterally: face (above eyebrow), hands (medial phalanx second and third digit), and feet (center dorsum). Beforehand, skin was cleaned at each stimulation site and local skin temperature was kept at >32°C to prevent alterations of skin conduction due to cutaneous influences. Twenty triple pulses were applied with two-fold intensity of the individual pain threshold (max. 2.4 mA, duration 0.5ms). At each individual stimulation site, the average pain threshold was determined by the subject reporting a pin-prick sensation using increasing current intensity. PREP potentials were recorded using a subcutaneous needle electrode from above Cz referred to linked earlobes (A1 -A2) of the international 10-20 system using Signal Software (version 2-16; Cambridge Electronic Design, Lt., UK).
Potentials were recorded using the following settings: gain: x 5000, bandwidth: 1 Hz -1 kHz, sweep length: 400 ms, digitalization sampling rate: 2.5 kHz. Two sets of averaged curves were investigated for reproducible N1-(i.e. first negative peak), P1-(i.e. subsequent positive peak) latencies and peak-to-peak amplitudes (PPA) using MATLAB software (version 7.7.0.471, The MathWorks, Ismaning, Germany) by an investigator blinded to subject allocation. All records were evaluated individually following a strict protocol as previously described (Papagianni et al., 2018; Siedler et al., 2019) and detailed in Supplementary Table   1 to exclude technical or biological artifacts. For standardization of the procedure and to keep attention at a comparable level, all subjects were asked to lie relaxed with eyes lightly closed and count the stimuli applied.
Skin punch biopsy
The intraepidermal nerve fiber density (IENFD) was determined on 5-mm skin punch biopsies (punch device by Stiefel, Offenbach, Germany) taken from the lateral lower leg (10 cm above the lateral malleolus) and upper thigh (20 cm below the anterior superior iliac spine). Skin samples were processed as described previously (Üçeyler et al., 2010) .
Samples were immunoreacted with antibodies against protein gene product-9.5 (PGP9.5, Ultraclone, UK, 1:800; primary antibody) with goat anti-rabbit IgG labeled with cyanine 3.18 fluorescent probe (Amersham, USA, 1:100; Cy3, secondary antibody), and the IENFD was quantified by an observer blinded to the identity of the specimen following published rules (Lauria et al., 2005) . The results were compared with our laboratory normative data base obtained from 180 healthy controls (124 women; median age: 50 years, 20-84; 56 men; median age 53 years, 22-76; normal values: calf 9 +/-3 fibers/mm, thigh 12 +/-4 fibers/mm). 
Statistical analysis
Results
Clinical data
QST shows impairment of small and large fibers in patients
Neuropathy patients had impaired large and small nerve fiber functions in QST (Fig.   1 ). Subgroup analysis was only performed in the largest cohort of patients with MFN and similarly showed elevated thresholds for thermal (p<0.01) and mechanical (p<0.001) stimulation compared to healthy controls (see Supplementary Figure 1 ). Numbers of pathological CDT, WDT, and TSL for small fiber function, and VDT for large fiber function when compared to lab-intern normative values of the three subgroups are shown in Supplementary Table 2 . QST was not able to distinguish between LFN, MFN, and SFN.
Patients with MFN have a distal loss of PREP and prolonged PREP latencies
PREP data of patients with LFN, MFN, and SFN are summarized in Supplementary   Table 3 . In healthy controls, PREP were missing (i.e. no reproducible potential) in 1/49 (2%) after stimulation at the face and 4/29 (8%) after stimulation at the foot. In patients, PREP were missing in 2/108 (2%) after stimulation at the face, in 5/108 (5%) after stimulation at the hand, and 19/108 (18%) after stimulation at the foot. Missing PREP were not included into quantitative data analysis. Table 3 shows the numbers of missing PREP after stimulation at face, hand, and foot in subgroups of patients with LFN, MFN, and SFN. A proximal to distal gradient for loss of PREP was found mainly in patients with MFN (Fig. 2) .
While PREP parameters did not differ between patients with LFN, SFN, and healthy controls after stimulation at face, hand, and foot, patients with MFN had longer N1-latencies than controls after stimulation at the foot ( ] ms, controls: 218 [135-394] ms, p<0.05; Fig. 3 ).
Demyelinating PNP are associated with prolonged PREP latencies
Patients with electrophysiological and/or histological signs of demyelinating PNP (n=30, including 24 MFN and 6 LFN) had prolonged PREP N1-and P1-latencies after stimulation at the hand when compared to healthy controls (p<0.05 each; Fig.4 ). Patients with axonal PNP (n= 51, including 42 MFN and 9 LFN) showed no intergroup difference for PREP latencies when compared to healthy controls.
PREP are often missing in patients with advanced neuropathy
When stratifying data for pathology in nerve conduction studies, PREP were missing after stimulation at the foot in 10/31 (32%) patients with no recordable sural nerve SNAP, while only in 4/49 (8%) healthy controls (χ 2 : p<0.05, Fig. 5A ). In contrast, PREP were missing in only 8/76 (10%) patients with preserved sural nerve potential (normal or pathological).
When stratifying our patient cohort for skin innervation, PREP were missing in 4/17 (24%) patients with loss of distal epidermal innervation (IENFD=0 fiber/mm) after stimulation at the foot, while only in 4/49 (8%) healthy controls (χ 2 : p<0.01 Fig. 5B ). In contrast, PREP were missing in only 7/60 (12%) patients with preserved skin innervation (normal or pathological). Patients with reduced proximal IENFD had a lower PREP PPA after stimulation at the face when compared to healthy controls (p<0.05, Fig. 6A ). PREP PPA of patients after stimulation at the face and proximal IENFD showed a positive correlation (p<0.05, Fig. 6B ).
No association was found for distal IENFD and PREP PPA.
Discussion
In this study, we prospectively examined A-delta fiber pathways in patients with LFN, MFN, and SFN using PREP. We report on prolonged latencies in patients with MFN and patients with demyelinating neuropathies, and absent PREP as indicator of advanced neuropathy. Impairment of small nerve fibers is a common finding in patients with neuropathy of different origin; in our cohort almost 80% of patients had clinical symptoms of small fiber damage. In patients with MFN, which was our largest patient subgroup, PREP revealed prolonged latencies after stimulation at the foot. Length-dependent vulnerability of nerve fibers is a common concept (Lauria et al., 1999) which may underlie our finding. Hence, PREP may be an effective and easy-to-apply tool in screening for small fiber pathology in patients with MFN in clinical routine.
Interestingly, there was also an association of demyelinating neuropathies with prolonged PREP latencies after stimulation at the hand. Since PREP mainly examines pathways of thinly myelinated A-delta fibers (Katsarava et al., 2006a) , this finding may hint towards different mechanisms of damage in axonal and demyelinating neuropathies, not only in large but also in small fibers. While C-fibers and A-delta fibers cannot be differentiated histologically using the routinely applied protein gene product 9.5 immunoreaction for assessment of skin innervation, PREP may provide a suitable tool for exclusively studying Adelta fibers. This might, in turn, be the reason for inconsistent findings when correlating IENFD with PREP PPA (Obermann et al., 2008; Üçeyler et al., 2013) .
Missing PREP were a common finding in our cohort of patients after stimulation at the foot. After exclusion of technical artifacts, we found an association between missing PREP with other indicators of advanced nerve fiber damage. First, the proximal to distal gradient of loss of PREP is in line with clinical and pathophysiological considerations of distally pronounced fiber damage. Second, missing PREP were three times more frequent in patients with no recordable sural nerve SNAP compared to those with preserved sural nerve SNAP. Third, PREP were also frequently missing in patients with loss of distal epidermal innervation. Hence, after careful conductance and exclusion of confounders, missing PREP indicate advanced small nerve fiber damage.
Data of our study is in line with previous findings in patients with SFN (Katsarava et al., 2006a; Obermann et al., 2008; Üçeyler et al., 2013; Papagianni et al., 2018) indicating selective examination of small fibers using PREP. Our study supports these findings by showing alterations only in patients with MFN and not in patients with LFN, and associations to pathological IENFD, length-dependency, and severity of disease.
Our study has several limitations. The patient cohort was inhomogeneous in terms of etiology and clinical presentation challenging subgroup analysis. Medication with potential influence on central nervous pathways was not paused. We did not perform skin biopsies in our control group.
In summary, PREP is an easy-to-apply and objective method for the examination of Adelta fibers in clinical practice also in patients with simultaneous large fiber pathology, and advanced fiber damage has to be considered in cases with loss of PREP. Missing pain-related evoked potentials (PREP) after stimulation at face, hand, and foot of patients with large fiber neuropathy (LFN), mixed fiber neuropathy (MFN), and small fiber neuropathy (SFN). N1-(light grey) and P1-latencies (dark grey) are prolonged after stimulation at the hand in patients with demyelinating polyneuropathy (PNP, n=30) in comparison to healthy controls (p<0.05). Patients with axonal PNP (n= 51) showed no intergroup difference. A: Patients with reduced proximal intraepidermal nerve fiber density (IENFD) had reduced peak to peak amplitude (PPA) of pain-related evoked potentials (PREP) after stimulation at the face (p<0.05). B: PREP PPA after stimulation at the face and proximal IENFD showed a positive correlation (p<0.05).
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